Interleukin-1-inducible MCPIP protein has structural and functional properties of RNase and participates in degradation of IL-1beta mRNAGerminal mutations of RET, SDHB, SDHD, and VHL genes in patients with apparently sporadic pheochromocytomas and paragangliomasGenome-wide association study on differentiated thyroid cancerTwo-miRNA classifiers differentiate mutation-negative follicular thyroid carcinomas and follicular thyroid adenomas in fine needle aspirations with high specificity.A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas.Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas.Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts.Analysis of cyclin D1 and retinoblastoma protein immunoreactivity in follicular thyroid tumors.Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawalAnalysis options for high-throughput sequencing in miRNA expression profilingAnterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells.B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progressionAssociation between polymorphisms in the TSHR gene and Graves' orbitopathy.13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study.Thyroid carcinoma: diagnostic and therapeutic approach; genetic background (review).Cabozantinib in progressive medullary thyroid cancer.Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma.The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report.Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCiMolecular changes in thyroid neoplasia.Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinomaPhase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialFollow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.Current genetic methodologies in the identification of disaster victims and in forensic analysisTranscriptional profiles of pilocytic astrocytoma are related to their three different locations, but not to radiological tumor features.Impact of SNPs on methylation readouts by Illumina Infinium HumanMethylation450 BeadChip Array: implications for comparative population studies.BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma.Differences in Gene-Gene Interactions in Graves' Disease Patients Stratified by Age of Onset.Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas.Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report.Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.Is there a need to redefine the upper normal limit of TSH?Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer?
P50
Q28118792-EF2FE72E-DF17-48F6-89C9-79D45D35B2B7Q28275066-BF37C4E7-B167-407B-8E9A-A81FF73C8894Q28943543-35C6E3D9-682B-4536-8852-3E55AF5ACFFCQ30313796-8EEAFE23-77CD-49C0-ACDA-6F9CA86E7809Q30317054-2051CBB9-9F47-4822-8E73-F5F257E989AFQ30317493-EB8AD79F-4051-4E50-8E3E-BA68196F7811Q30992731-39F42787-03B0-401B-983C-DE97FCB054C8Q33215949-0468DBE6-DEE6-4BA7-BC1F-672CDA722A01Q33463820-15F3E629-BBDA-4361-A355-698591488570Q33557722-66BCA2FC-BEA5-4B40-9DF1-0A3C00481784Q33890655-11D0A9D0-46DC-45F5-AEBF-ABBFFD081CD8Q33934897-852CBB6F-0728-439D-8622-C910B0AD3DFCQ33951536-0B07F422-C04A-456C-A9D8-2DFECB7411B3Q34018753-FA1F06E8-A00A-4479-984E-23B6D0AD0303Q34035598-2A09A053-D641-4C82-9A4A-9638695BB57DQ34185084-D7254E91-55C2-4706-9140-571BB277E8FFQ34276843-CFE6B923-6552-42E2-A733-24784F572511Q34331382-7B0EEB2A-1FFE-4F0C-8527-442C737C5BDDQ34341331-14490594-85F8-4F99-8A49-127CA9B2F7E5Q34512677-76693142-EF55-470B-8EA6-AB1D7C739165Q34716574-7F484754-CFFF-4838-B522-5E83E54983C0Q34778280-92458B45-D0AF-4F31-AB4C-7A8B30111599Q34989774-B2864813-ED5E-4528-88F1-AEF92AC92006Q35160562-CE106633-6C7A-44EA-9EFA-6524787BBED7Q35195766-B5BBEBF1-7B88-4C3C-852C-28EFA34F9E86Q35649218-6B270229-203C-4FAE-BA6A-19C74C4B24E9Q35693617-AFB7CE67-DB81-4E35-8A59-199FA5DF40CAQ35819975-6FA29A32-8A58-4A06-919B-7CFB8E0C95B7Q35852853-F6581412-A00C-42D9-B50C-A26AE3059B43Q35857363-4C39F768-6B81-4FA4-800C-D86A5CB3D6E5Q35946146-48675CB3-5AB4-4C5E-B56B-3CBD826F4E8CQ36037071-CD3FA26A-2A3D-4854-A73C-46669A48CC59Q36078981-9A59DC4F-1ABC-4D44-99A1-6AA4CE86AF10Q36239261-D4677646-36E6-43FC-B5DB-C0E5ED59D445Q36299076-03012507-0C96-4359-B2A4-D7C3B96167FBQ36302100-71385163-9450-4C33-959F-6D14D07EB842Q36328600-D2764ACD-F690-43FC-A6EF-4519CF7A61A4Q36431628-D2FADC3D-5898-4632-B2E7-B2876639FDC9Q36462681-FD1B3439-6FD4-4B53-9345-372DEFA5F1CCQ36643368-14E42D29-691C-4D07-988E-707DE26D6219
P50
description
Polish physician, endocrine oncologist, and cancer researcher
@en
Pools arts
@nl
chercheuse polonaise
@fr
investigador
@es
polnische Forscherin
@de
polska lekarka, zajmująca się endokrynologią onkologiczną i badaniami w tym zakresie
@pl
研究者
@zh
name
Barbara Jarząb
@ast
Barbara Jarząb
@ca
Barbara Jarząb
@cs
Barbara Jarząb
@da
Barbara Jarząb
@de
Barbara Jarząb
@en
Barbara Jarząb
@es
Barbara Jarząb
@fr
Barbara Jarząb
@ga
Barbara Jarząb
@gl
type
label
Barbara Jarząb
@ast
Barbara Jarząb
@ca
Barbara Jarząb
@cs
Barbara Jarząb
@da
Barbara Jarząb
@de
Barbara Jarząb
@en
Barbara Jarząb
@es
Barbara Jarząb
@fr
Barbara Jarząb
@ga
Barbara Jarząb
@gl
altLabel
Barbara Jarzab
@en
prefLabel
Barbara Jarząb
@ast
Barbara Jarząb
@ca
Barbara Jarząb
@cs
Barbara Jarząb
@da
Barbara Jarząb
@de
Barbara Jarząb
@en
Barbara Jarząb
@es
Barbara Jarząb
@fr
Barbara Jarząb
@ga
Barbara Jarząb
@gl
P214
P106
P1153
7004634791
P1412
P1559
Barbara Jarząb
@pl
P19
P21
P213
0000 0001 1123 1945
P214
P27
P31
P3124
P496
0000-0001-9811-9584
P569
1952-04-24T00:00:00Z
P735
P7859
viaf-161613787